ERBB2 and breast cancer: Standard of care (SoC) for first-line (1L) treatment of patients with HER2+ metastatic BC (mBC) is pertuzumab, trastuzumab, and taxane chemotherapy as induction therapy, followed by maintenance treatment with pertuzumab and trastuzumab [9].